Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 10/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591681 | 0.91 | PDK4 (0.44) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL4532704 | 0.88 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL30570071 | 0.88 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12566963 | 0.88 | PDK4 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL2003552 | 0.87 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12074148 | 0.87 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL6662189 | 0.87 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL28161050 | 0.87 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL2349369 | 0.87 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL26134753 | 0.87 | USP2 (0.44) | PDK4ESR2NR1H2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4722219-A1 | CEREBELLAR PROTEIN E3 UBIQUITIN LIGASE INHIBITOR AND CHIMERIC COMPOUND TARGETING PROTEIN DEGRADATION | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-1694676-A1 | SPIROINDOLINE DERIVATIVES HAVING INSECTICIDAL PROPERTIES | Syngenta Participations AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005061500-A1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005058897-A1 | SPIROINDOLINE DERIVATIVES HAVING INSECTICIDAL PROPERTIES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | PDK4 691/4885GRM5 1883/4885GRM1 1472/4885 |
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | MALT1, CCR10, CYP51A1 | PDK4 4296/4885GRM5 4549/4885GRM1 3110/4885 |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | MALT1, NR3C2, MRPL21 | PDK4 4476/4885GRM5 4302/4885GRM1 1803/4885 |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | PDK4 4412/4885GRM5 1301/4885GRM1 644/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | PDK4 3928/4885GRM5 433/4885GRM1 134/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | PDK4 2984/4885GRM5 735/4885GRM1 200/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | PDK4 4130/4885GRM5 1142/4885GRM1 585/4885 |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | PDK4 3466/4885GRM5 3486/4885GRM1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.